Daniel T Fagan, PH.D

Vice Chairman

Dr. Fagan was appointed as a director of Synthetech, Inc. in 2001 and was Chairman of the Board from 2005 until the company was sold to W.R. Grace & Co. in November 2010. He served as the sole member of the Board’s Strategic Development Committee from February 2006 through October 2006. Between November 2006 and June 2008, Dr. Fagan served as the Chief Executive Officer of Synthetech.

Dr. Fagan was President and CEO and a director of PepTx, Inc., a private early stage pharmaceutical company that is developing peptide based oncology therapeutics from January 2004 through September 2006. Dr. Fagan continues to serve as a director of PepTx. From July 2001 through 2003, Dr. Fagan was President of ProGen Biologics LLC, a private biopharmaceutical company that develops healthcare solutions for people suffering from autoimmune diseases. In addition, since November 2000, Dr. Fagan has also served as a consultant to the pharmaceutical and emerging pharmaceutical industries.

From 1992 to 2000, Dr. Fagan was employed as the General Manager of Peptides by Mallinckrodt, Inc., a subsidiary of Tyco International that manufactures bulk pharmaceuticals. From 1978 to 1991, he was employed in various capacities, including President, from 1987 to 1991, of Sigma Chemical, a subsidiary of Sigma Aldrich Corporation that manufactures fine chemicals.

Dr. Fagan holds a B.A. in Chemistry from Otterbein College and a Ph.D. in Chemistry from Case Western Reserve University.

Direct: 314.954.6554 | Fax: 917.591.3200 | Email: dfagan@brocair.com